Cover Image
Market Research Report

Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy

Published by GBI Research Product code 252730
Published Content info 113 Pages
Immediate Delivery Available
Price
Back to Top
Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy
Published: October 15, 2012 Content info: 113 Pages
Description

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy", which provides insights into the global hepatitis C therapeutics market up to 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report examines the global hepatitis C treatment usage patterns, and the geographical distribution of hepatitis C therapeutics and markets across the US, the top five countries of Europe and Japan. The report also includes insights into the hepatitis C therapeutics R&D product pipeline and explores the competitive landscape, including major players in the hepatitis C therapeutics market. Finally, the report also includes analysis of the Mergers and Acquisitions (M&As) and licensing agreements that took place in the hepatitis C therapeutics market from 2010 to 2012.

In 2011, the hepatitis C therapeutics market was estimated at $2.6 billion. From 2004 to 2011, the market grew at the CAGR of 2.7%, with the launch of Incivek and Victrelis in 2011 boosting positive growth. The market had seen a significant decline in value due to the low uptake of Pegylated Interferon (PI) therapies and subsequent patient warehousing in anticipation of more effective drugs being launched. The launch of the two PIs added a billion dollars to the market in 2011 and helped to achieve a positive CAGR. GBI Research analyses estimate that the hepatitis C therapeutics market in the top seven markets will be valued at $14.9 billion in 2018, with a CAGR of 28.3% over the forecast period. These estimates are based on the continued adoption of PIs as the gold standard treatment option for hepatitis C, and the imminent launch of oral DAA molecules, the first of which should be in the market in 2015. Further, combinations of DAA drugs will improve the overall effectiveness of treatment and will have less side-effects than PIs. This should result in a significant increase in diagnosis and treatment rates over the forecast period.

Scope

  • Data and analysis on the hepatitis C therapeutics market in the leading geographies of the world - the US, Japan, the UK, Germany, France, Italy and Spain.
  • Annualized market data for the hepatitis C therapeutics market from 2004 to 2011, with forecasts to 2018.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global hepatitis C therapeutics market including top companies benchmarking. The key companies studied in this report are Vertex Pharmaceuticals, Inc., Merck & Co., Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company (BMS), Abbott Laboratories, F. Hoffmann-La Roche Ltd., Johnson & Johnson / Tibotec BVBA, Boehringer Ingelheim GmbH, Novartis AG, Achillion Pharmaceuticals, Inc., and Idenix Pharmaceuticals, Inc.
  • Key M&A activities and licensing agreements that took place in the years 2010 to 2012 in the hepatitis C therapeutics market.

Reasons to buy

  • Align their product portfolios to markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Devise a more tailored strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Executive Summary

Incivek and Victrelis to Kick-Start Huge Hepatitis C Market Growth

The approval of the US Food and Drug Administration in May of last year for two drugs, Incivek and Victrelis, has sparked explosive pharmaceutical industry revenue gains that will see the hepatitis C market grow exponentially in size by 2018, predicts new research by healthcare sector analysts GBI Research.

The firm's latest report* states that the market for hepatitis C will climb from a 2011 value of $2.6 billion to just under $15 billion by the end of 2018, at a Compound Annual Growth Rate (CAGR) of 28%.

According to GBI Research, last year's introduction of Incivek (co-developed by Vertex and Johnson & Johnson) and Victrelis (from US firm, Merck & Co.) marked the beginning of a boom period for the global hepatitis C market following years of sliding revenues.

Both of these highly influential treatments will be subject to large-scale marketing across the US, Europe and Japan in the coming years and will contribute significantly to the industry's value.

Drug manufacturer profits are expected to be further bolstered by the imminent launch of oral DAA molecules (the first of which should be on the market in 2015) and the increased reliance on prescribing DAA drug combinations within the healthcare community.

Almost 8 million people worldwide were estimated to have chronic hepatitis C virus (HCV) in 2011, climbing from 7.6 million in 2004. Thanks to improving treatments and an increasing awareness within the general population, GBI Research expects this figure to drop below the 7 million mark by 2018.

Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy

This report provides insights into the global hepatitis C therapeutics market up to 2018.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

3. Market Overview

  • 3.1. Introduction
    • 3.1.1. HCV Classification
    • 3.1.2. HCV Genome
    • 3.1.3. HCV Diagnosis
    • 3.1.4. HCV Treatment Goals
    • 3.1.5. Current HCV Treatment Options
    • 3.1.6. Future HCV Treatment Paradigm
  • 3.2. Global Hepatitis C Therapeutics Market
    • 3.2.1. Revenue
    • 3.2.2. Annual Cost of Therapy
    • 3.2.3. Treatment Usage Pattern
    • 3.2.4. Market Trends

4. Geographic Landscape

  • 4.1. The US
    • 4.1.1. Revenue
    • 4.1.2. Annual Cost of Therapy
    • 4.1.3. Treatment Usage Pattern
  • 4.2. Top Five Countries of Europe
    • 4.2.1. Revenue
    • 4.2.2. Revenue by Country
    • 4.2.3. Annual Cost of Therapy
    • 4.2.4. Treatment Usage Pattern
  • 4.3. Japan
    • 4.3.1. Revenue
    • 4.3.2. Annual Cost of Therapy
    • 4.3.3. Treatment Usage Pattern
  • 4.4. Other Markets
    • 4.4.1. Australia
    • 4.4.2. China
    • 4.4.3. India

5. Pipeline Analysis

  • 5.1. Research and Development Pipeline
  • 5.2. Highlights from the International Liver Congress 2012, European Association for the Study of the Liver
  • 5.3. Recently Launched
    • 5.3.1. Incivek/Telavic/Incivo (telaprevir)
    • 5.3.2. Victrelis
    • 5.3.3. Perspective on Incivek and Victrelis
  • 5.4. Most Promising Molecules in Phase III
    • 5.4.1. GS-7977
    • 5.4.2. BMS-790052(daclatasvir)
    • 5.4.3. TMC-435
    • 5.4.4. BI-201335
  • 5.5. Most Promising Molecules in Phase II
    • 5.5.1. ABT-450
    • 5.5.2. GS-5885
    • 5.5.3. RG7128(mericitabine)
    • 5.5.4. ACH-1625
  • 5.6. Combination Therapy Development
    • 5.6.1. With PEG-IFN and RBV
    • 5.6.2. With RBV only
    • 5.6.3. Without PEG-IFN and RBV

6. Competitive Landscape

  • 6.1. Market Share Analysis
  • 6.2. Competitive Profiling
    • 6.2.1. Vertex Pharmaceuticals, Inc.
    • 6.2.2. Merck & Co., Inc.
    • 6.2.3. Gilead Sciences, Inc.
    • 6.2.4. Bristol-Myers Squibb Company
    • 6.2.5. Abbott Laboratories
    • 6.2.6. F. Hoffmann-La Roche Ltd.
    • 6.2.7. Johnson & Johnson/Tibotec BVBA
    • 6.2.8. Boehringer Ingelheim GmbH
    • 6.2.9. Novartis AG
    • 6.2.10. Achillion Pharmaceuticals, Inc.
    • 6.2.11. Idenix Pharmaceuticals, Inc.

7. Strategic Consolidations

  • 7.1. Deals by Year
  • 7.2. Deals by Type
  • 7.3. Deals by Value
  • 7.4. Deals by Region
  • 7.5. Mergers and Acquisitions
    • 7.5.1. Major M&A Deals
  • 7.6. Licensing Agreements
    • 7.6.1. Major Licensing Agreements
  • 7.7. Partnerships
    • 7.7.1. Major Partnership Deals

8. Appendix

  • 8.1. Market Definitions
  • 8.2. Abbreviations
  • 8.3. Bibliography
  • 8.4. Research Methodology
    • 8.4.1. Coverage
    • 8.4.2. Secondary Research
    • 8.4.3. Primary Research
    • 8.4.4. Therapeutic Landscape
    • 8.4.5. Market Size by Geography
    • 8.4.6. Geographical Landscape
    • 8.4.7. Pipeline Analysis
    • 8.4.8. Competitive Landscape
    • 8.4.9. Expert Panel Validation
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Characteristics of HCV Genotypes 1-3
  • Table 2: Functions of HCV Proteins and Therapeutic Approach
  • Table 3: Clinical Endpoints for HCV Therapy
  • Table 4: Patient Classification Based on Viral Response to Therapy
  • Table 5: Direct-acting Antiviral Therapies in Development
  • Table 6: Host-Targeting Antiviral Therapies in Development
  • Table 7: Novel Interferons in Development
  • Table 8: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2004-2011
  • Table 9: Hepatitis C Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
  • Table 10: Hepatitis C Therapeutics Market, Global, Revenues by Geography ($m), 2004-2011
  • Table 11: Hepatitis C Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2011-2018
  • Table 12: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2004-2011
  • Table 13: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 14: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, Population ('000), 2004-2011
  • Table 15: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, Population ('000), 2011-2018
  • Table 16: Hepatitis C Therapeutics Market, The US, Revenues ($m), 2004-2011
  • Table 17: Hepatitis C Therapeutics Market, The US, Revenue Forecasts ($m), 2011-2018
  • Table 18: Hepatitis C Therapeutics Market, The US, Annual Cost of Therapy ($), 2004-2011
  • Table 19: Hepatitis C Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2018
  • Table 20: Hepatitis C Therapeutics Market, The US, Treatment Usage Pattern, Population ('000), 2004-2011
  • Table 21: Hepatitis C Therapeutics Market, The US, Treatment Usage Pattern, Population ('000), 2011-2018
  • Table 22: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2004-2011
  • Table 23: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018
  • Table 24: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenues by Country ($m), 2004-2011
  • Table 25: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts by Country ($m), 2011-2018
  • Table 26: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2004-2011
  • Table 27: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2011-2018
  • Table 28: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern, Population ('000), 2004-2011
  • Table 29: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern, Population ('000), 2011-2018
  • Table 30: Hepatitis C Therapeutics Market, Japan, Revenue ($m), 2004-2011
  • Table 31: Hepatitis C Therapeutics Market, Japan, Revenue Forecasts ($m), 2011-2018
  • Table 32: Hepatitis C Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011
  • Table 33: Hepatitis C Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018
  • Table 34: Hepatitis C Therapeutics Market, Japan, Treatment Usage Pattern, Population ('000), 2004-2011
  • Table 35: Hepatitis C Therapeutics Market, Japan, Treatment Usage Pattern, Population ('000), 2011-2018
  • Table 36: Hepatitis C Therapeutics Market, Australia, Pipeline Analysis, 2012
  • Table 37: Hepatitis C Therapeutics Market, China, Factors Associated with HCV Infection
  • Table 38: Hepatitis C Therapeutics Market, China, Pipeline Analysis, 2012
  • Table 39: Hepatitis C Therapeutics Market, India, Pipeline Analysis, 2012
  • Table 40: Hepatitis C Therapeutics Market, Global, Notable Interferon-free Therapy Regimens Presented at EASL 2012
  • Table 41: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Recently Launched Products, 2012
  • Table 42: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, ADVANCE Phase III Study Results
  • Table 43: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, ILLUMINATE Phase III Study Results
  • Table 44: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, REALIZE Phase III Study Results
  • Table 45: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Most Promising Molecules in Phase III, 2012
  • Table 46: Hepatitis C Therapeutics Market, Global, GS-7977, Phase III Program
  • Table 47: Hepatitis C Therapeutics Market, Global, GS-7977, The QUANTUM Study Results
  • Table 48: Hepatitis C Therapeutics Market, Global, GS-7977, The ELECTRON Study Results
  • Table 49: Hepatitis C Therapeutics Market, Global, GS-7977, Partnership with BMS-790052, Study Results
  • Table 50: Hepatitis C Therapeutics Market, Global, TMC-435, The Phase III Program
  • Table 51: Hepatitis C Therapeutics Market, Global, TMC-435, ASPIRE Study, Efficacy Results
  • Table 52: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C1 Study Results
  • Table 53: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C2 Study Efficacy Results
  • Table 54: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C2 Study Safety Results
  • Table 55: Hepatitis C Therapeutics Market, Global, BI-201335, The SOUND-C2 Study Results
  • Table 56: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Most Promising Molecules in Phase II, 2012
  • Table 57: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Combination Therapies with PEG-IFN and RBV, 2012
  • Table 58: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Combination Therapies with RBV, 2012
  • Table 59: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Combination Therapies without PEG-IFN and RBV, 2012
  • Table 60: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Mergers and Acquisitions, 2010-2012
  • Table 61: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Licensing Agreements, 2010-2012
  • Table 62: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Partnerships, 2010-2012

List of Figures

  • Figure 1: Hepatitis C, Global, Prevalence (million) and Genotype Distribution, 2011
  • Figure 2: Hepatitis C Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018
  • Figure 3: Hepatitis C Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2004-2018
  • Figure 4: Hepatitis C Therapeutics Market, Global, Branded and Generic Product Share (%), 2011 and 2018
  • Figure 5: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2004-2018
  • Figure 6: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, Population ('000), 2004-2018
  • Figure 7: Hepatitis C Therapeutics Market to 2018, Global, Market Trends, Drivers and Barriers
  • Figure 8: Hepatitis C Therapeutics Market, The US, Revenue Forecasts ($m), 2004-2018
  • Figure 9: Hepatitis C Therapeutics Market, The US, Annual Cost of Therapy ($), 2004-2018
  • Figure 10: Hepatitis C Therapeutics Market, The US, Treatment Usage Pattern, Population ('000), 2004-2018
  • Figure 11: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2004-2018
  • Figure 12: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts by Country ($m), 2004-2018
  • Figure 13: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2004-2018
  • Figure 14: Hepatitis C Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern, Population ('000), 2004-2018
  • Figure 15: Hepatitis C Therapeutics Market, Japan, Revenue Forecasts ($m), 2004-2018
  • Figure 16: Hepatitis C Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018
  • Figure 17: Hepatitis C Therapeutics Market, Japan, Treatment Usage Pattern, Population ('000), 2004-2018
  • Figure 18: Hepatitis C Therapeutics Market, China, Revenue ($m), 2007-2011
  • Figure 19: Hepatitis C Therapeutics Market, India, Revenue ($m), 2007-2011
  • Figure 20: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Molecules in Development by Phase, May 2012
  • Figure 21: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, ADVANCE Phase III Study Design
  • Figure 22: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, ILLUMINATE Phase III Study Design
  • Figure 23: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Incivek, REALIZE Phase III Study Design
  • Figure 24: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Victrelis, SPRINT-2 Phase III Study Design
  • Figure 25: Hepatitis C Therapeutics Market, Global, Pipeline Analysis, Victrelis, RESPOND-2 Phase III Study Design
  • Figure 26: Hepatitis C Therapeutics Market, Global, GS-7977, The QUANTUM Study Design
  • Figure 27: Hepatitis C Therapeutics Market, Global, GS-7977, The ELECTRON Study Design
  • Figure 28: Hepatitis C Therapeutics Market, Global, GS-7977, The PROTON Study Design
  • Figure 29: Hepatitis C Therapeutics Market, Global, GS-7977, The ATOMIC Study Design
  • Figure 30: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C1 Study Design
  • Figure 31: Hepatitis C Therapeutics Market, Global, BI-201335, The SILEN-C2 Study Results
  • Figure 32: Hepatitis C Therapeutics Market, Global, Mericitabine, The PROPEL Study Design
  • Figure 33: Hepatitis C Therapeutics Market, Global, Mericitabine, The INFORM-SVR Study Design
  • Figure 34: Hepatitis C Therapeutics Market, Global, Competitive Landscape, Market Share (%), 2011
  • Figure 35: Hepatitis C Therapeutics Market, Global, Vertex Pharmaceuticals, SWOT Analysis
  • Figure 36: Hepatitis C Therapeutics Market, Global, Merck and Co., SWOT Analysis
  • Figure 37: Hepatitis C Therapeutics Market, Global, Gilead Sciences, SWOT Analysis
  • Figure 38: Hepatitis C Therapeutics Market, Global, Bristol-Myers Squibb Company, SWOT Analysis
  • Figure 39: Hepatitis C Therapeutics Market, Global, Abbott Laboratories, SWOT Analysis
  • Figure 40: Hepatitis C Therapeutics Market, Global, F. Hoffmann-La Roche, SWOT Analysis
  • Figure 41: Hepatitis C Therapeutics Market, Global, Johnson & Johnson/Tibotec, SWOT Analysis
  • Figure 42: Hepatitis C Therapeutics Market, Global, Boehringer Ingelheim, SWOT Analysis
  • Figure 43: Hepatitis C Therapeutics Market, Global, Novartis, SWOT Analysis
  • Figure 44: Hepatitis C Therapeutics Market, Global, Achillion Pharmaceuticals, SWOT Analysis
  • Figure 45: Hepatitis C Therapeutics Market, Global, Idenix Pharmaceuticals, SWOT Analysis
  • Figure 46: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Year, 2010-2012
  • Figure 47: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Type, 2010-2012
  • Figure 48: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Value, 2010-2012
  • Figure 49: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Region, 2010-2012
  • Figure 50: GBI Research Market Forecasting Model
Back to Top